Neurocrine Bioscience Inc., of San Diego, said it started a 36-patient, open-label, multidose, two-week study of NBI-98854, a small-molecule vesicular monoamine transporter 2, or VMAT2, inhibitor, in both children and adolescents with Tourette syndrome.